Ocular Therapeutix Inc
Research Ocular Therapeutix Inc (OCUL) on Bullrun: market cap USD 2.39B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOCUL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.39B
- Financial periodQ2 2026
- RevenueUSD 13.48M
- Net income-USD 78.76M
- Free cash flow-USD 70.64M
- Gross margin85.1%
Valuation Snapshot
latest market cap is USD 2.39B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 51.95M | -USD 265.94M | -USD 216.89M | 87.3% | -1.42 | USD 737.06M | USD 76.97M | USD 654.31M |
| FY2024 | USD 63.72M | -USD 193.51M | -USD 135.97M | 91.2% | -1.22 | USD 392.10M | USD 75.78M | USD 315.34M |
| FY2023 | USD 58.44M | -USD 80.74M | -USD 76.32M | 91.0% | -1.02 | USD 195.81M | USD 83.39M | USD 91.13M |
| FY2022 | USD 51.49M | -USD 71.04M | -USD 63.32M | 91.2% | -0.97 | USD 102.30M | USD 59.47M | USD 35.38M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.39B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.62B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.35B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 512.18M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 216.40M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 534.82M | n/a | n/a | n/a |
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Ocular Therapeutix Inc's market cap?
Ocular Therapeutix Inc's market capitalization is USD 2.39B.
What does Ocular Therapeutix Inc do?
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.